Oxygen

Orphan designation: anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein,anti-CD7 mAb (WT1)-ricin A chain fusion protein Treatment of graft-versus-host disease, 26/08/2005 Positive

Retrieved on: 
Thursday, April 18, 2024
Community, Eurostat, Civil service commission, Diagnosis, CD7, Graft-versus-host disease, Cell, Bone marrow, Disease, Patient, Committee, Extrapyramidal system, Tissue, Knowledge, Antibody, Regulation, EMA, IRIS, Protein, CD3, BV, European, Skin, WT1, COMP, Oxygen, Immune system, European Commission, Safety, Hematopoietic stem cell transplantation, Stomach, Liver, Pharmaceutical industry

Orphan designation: anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein,anti-CD7 mAb (WT1)-ricin A chain fusion protein Treatment of graft-versus-host disease, 26/08/2005 Positive

Key Points: 


Orphan designation: anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein,anti-CD7 mAb (WT1)-ricin A chain fusion protein Treatment of graft-versus-host disease, 26/08/2005 Positive

Orphan designation: Synthetic hypericin Treatment of cutaneous T-cell lymphoma, 28/07/2015 Positive

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, X-ray, Growth, Medicine, Disease, Patient, Ageing, Committee, Knowledge, Tissue, Neoplasm, Light, Cutaneous T-cell lymphoma, Regulation, Cancer, EMA, IRIS, Quality of life, Reactive oxygen species, Lymph, CTCL, Clinical trial, European, Skin, COMP, Oxygen, European Commission, Immune system, Safety, Carmustine, Alfa, Marketing, Lymphatic system, Pharmaceutical industry

Orphan designation: Synthetic hypericin Treatment of cutaneous T-cell lymphoma, 28/07/2015 Positive

Key Points: 


Orphan designation: Synthetic hypericin Treatment of cutaneous T-cell lymphoma, 28/07/2015 Positive

Aperam BioEnergia kicks off Patch partnership by selling 15,000 metric tons of carbon removal

Retrieved on: 
Wednesday, April 10, 2024
Jequitinhonha River, Heat, Partnership, Global warming potential, Sale, Stainless steel, Carbon, Oxygen, Soil, Biomass

Luxembourg, 2 April 2024 (10:00 CET) - Aperam BioEnergia, unit of the Aperam Recycling & Renewables Division located in Brazil, has recently partnered with Patch, a global platform connecting carbon credit buyers and sellers, to sell biochar carbon credits on the voluntary carbon market.

Key Points: 
  • Luxembourg, 2 April 2024 (10:00 CET) - Aperam BioEnergia, unit of the Aperam Recycling & Renewables Division located in Brazil, has recently partnered with Patch, a global platform connecting carbon credit buyers and sellers, to sell biochar carbon credits on the voluntary carbon market.
  • The new partnership has already resulted in the sale of 15,000 metric tons of biochar carbon removal.
  • Aperam began its first delivery via Patch in January this year, providing a certificate of 8.5 thousand tons of CO2e removed.
  • These certificates originate from biochar applied to the soil in Aperam BioEnergia planted forests, located in the Jequitinhonha Valley.

PDT (PDT) Is Now Available for Trading on LBank Exchange

Retrieved on: 
Friday, March 29, 2024
Blood, Blockchain, Cancer, Investment, Neoplasm, Decentralized finance, Oxygen, Ecosystem, Cryptocurrency

PDT (PDT) on the SNOWSEED platform introduces a Web3 economy that integrates blockchain into healthcare to foster a broad ecosystem where $PDT serves as a key medium of value exchange, enhancing user involvement and experiences across various industries.

Key Points: 
  • PDT (PDT) on the SNOWSEED platform introduces a Web3 economy that integrates blockchain into healthcare to foster a broad ecosystem where $PDT serves as a key medium of value exchange, enhancing user involvement and experiences across various industries.
  • LBank Exchange is thrilled to announce the upcoming listing of PDT (PDT), an innovative and advanced treatment modality for cancer, leveraging the power of light-sensitive drugs known as photosensitizers, along with light exposure, to destroy cancer cells.
  • The Snowseed Platform, through the WiseAlya Project, aims to revolutionize the way PDT is utilized and commercialized, particularly in Indonesia.
  • This development is a key component of the WiseAlya Project's strategy to introduce more effective and patient-friendly PDT treatments in Indonesia.

Heineken® shows the depth it will go to deliver the perfect pint with giant spirit level measuring bars across the world

Retrieved on: 
Tuesday, April 9, 2024
Giant, Natural Ingredients, Friends, Head, Taste, TVC, Science, Silver, Risk, Light, Motion, Table, Glass, Red star, System, Oxygen, Fruit, Beer, Heineken

AMSTERDAM, April 09, 2024 (GLOBE NEWSWIRE) -- With 25 million serves of Heineken® across 192 countries every single day*, there is a true science to maintaining its perfectly balanced taste and refreshment. From 100% Natural Ingredients, Heineken®’s famous A-Yeast and Horizontal Fermentation Tanks – and now a ‘Beer Level’ - a ‘highly scientific’, Heineken® filled spirit level to ensure bars and tables across the globe are perfectly flat to guarantee the perfect pint presentation!

Key Points: 
  • It comes as part of a wider global campaign that shows its consistent refreshment, thanks to the beer’s perfectly balanced taste and premium quality.
  • The campaign sees Heineken® Master Brewer Willem van Waesberghe exclusively reveal how to spot the perfectly poured pint.
  • Black Axe Mangal’ to showcase how its five-star premium brewing credentials delivers the perfect platform to transition your day from work mode to evening mode.
  • The playful ‘Beer Level’ comes as Heineken® today launches its global campaign and TVC ‘The First Ahhh!’.

GDC Unveils Its Next Leap into the Fusion of Art and AI-Generated Video Technology with a Captivating Short Film "Forgotten Planet"

Retrieved on: 
Monday, April 8, 2024
Astronaut, Uncertainty, Communication, Social media, AI, Catalysis, Animation, Oxygen, Creativity, Family, Entertainment

The short film combines captivating storytelling with AI-generated video technology, aiming to push the boundaries of creativity and innovation in the filmmaking industry.

Key Points: 
  • The short film combines captivating storytelling with AI-generated video technology, aiming to push the boundaries of creativity and innovation in the filmmaking industry.
  • The gripping narrative follows Astronaut Mark, stranded on an enigmatic alien world following a catastrophic space mission failure.
  • By integrating AI technology, the film not only elevates visual storytelling but also unlocks new realms of creative expression and innovation.
  • For more information about "Forgotten Planet" and to view the full video, visit AI Catalysis’s website at: https://aicatalysis.com/ .

Bestqool Revolutionizes Outdoor Activities with Innovative Red Light Therapy Devices

Retrieved on: 
Wednesday, April 3, 2024
RLT, Psoriasis, Motivation, Exercise, Chemical oxygen demand, System, Mitochondrion, Motion, Joint, Life, Athlete, Acne, Facial muscles, Skin, Oxygen, Red light, Health, Low-level laser therapy, Medical imaging

Seattle, Washington, April 03, 2024 (GLOBE NEWSWIRE) -- Bestqool has announced its innovative approach to integrating Red Light Therapy (RLT) with outdoor exercises and sports routines.

Key Points: 
  • Seattle, Washington, April 03, 2024 (GLOBE NEWSWIRE) -- Bestqool has announced its innovative approach to integrating Red Light Therapy (RLT) with outdoor exercises and sports routines.
  • Red Light Therapy is an advanced therapy mode that uses low-level wavelengths of red light to focus on the skin or deeper tissues, as needed to help resolve their related issues.
  • [2]
    Because of the invention of several hand-held devices, using Red Light Therapy within the comforts of your home has also been made possible.
  • When it comes to talking about top-notch, great-quality hand-held Red Light Therapy devices, Bestqool is your ultimate solution.

UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Wednesday, April 3, 2024
Kidney, UHN, User experience, AKI, Patient, Kidney disease, Inflammation, ACTU, Ethics, TMX Group, Pain management, Acute kidney injury, Ischemia, Injury, IRI, Science Advances, Arch, Oxygen, Reperfusion, Placebo-controlled study, Phase, University Health Network, OTCQB, Liver, Yolo Bypass, Randomness

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .
  • There is no treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, April 1, 2024
Research, Conference, Lupus, Inflammation, Patient, Food and Drug Administration, CTA, Doctor of Philosophy, SLE, Insurance, GRI, IPF, Fibrosis, Oxygen, Immune system, Injury, NKT, Food, Movement, Lupus nephritis, Autoimmune disease, Natural killer T cell, Medication, Pharmaceutical industry

LA JOLLA, CA, April 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the fiscal year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream.
  • GRI Bio’s lead program, GRI-0621, is a small molecule RAR-βɣ dual agonist that inhibits the activity of human iNKT cells.
  • Research and development expenses were $3.2 million and $0.2 million for the years ended December 31, 2023 and 2022, respectively.
  • General and administrative expenses were $8.2 million and $2.0 million for the years ended December 31, 2023 and 2022, respectively.

FDA Accepts Filing of New Drug Application for Nalmefene Auto-injector for the Treatment of Known or Suspected Opioid Overdose

Retrieved on: 
Monday, April 8, 2024
General Health, FDA, Health, Pharmaceutical, Medical Supplies, Hypoventilation, Hypersensitivity, Nalmefene, Pulmonary edema, Caregiver, Safety, Tachycardia, Risk, New Drug Application, Patient, Ventricular tachycardia, Naloxone, Health care, Buprenorphine, Mortality, NDA, MD, Methadone, Ventricular fibrillation, Hypotension, Oxygen, LAAM, Recurrence, Allergy, Purdue University, Hypertension, Fentanyl, Pharmaceutical industry

Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.

Key Points: 
  • Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.
  • "Through this auto-injector FDA submission, our goal is to help expand the availability of nalmefene to the community alongside existing available options for healthcare professionals.
  • Priority review status means that FDA will expedite the review process to evaluate a drug that would significantly improve treatment of a serious condition.
  • Nalmefene Hydrochloride Injection is indicated in the management of known or suspected opioid overdose.